Literature DB >> 11264454

Regulation and role of adenylyl cyclase isoforms.

J Hanoune1, N Defer.   

Abstract

At least nine closely related isoforms of adenylyl cyclases (ACs), the enzymes responsible for the synthesis of cyclic AMP (cAMP) from ATP, have been cloned and characterized in mammals. Depending on the properties and the relative levels of the isoforms expressed in a tissue or a cell type at a specific time, extracellular signals received through the G-protein-coupled receptors can be differentially integrated. The present review deals with various aspects of such regulations, emphasizing the role of calcium/calmodulin in activating AC1 and AC8 in the central nervous system, the potential inhibitory effect of calcium on AC5 and AC6, and the changes in the expression pattern of the isoforms during development. A particular emphasis is given to the role of cAMP during drug and ethanol dependency and to some experimental limitations (pitfalls in the interpretation of cellular transfection, scarcity of the invalidation models, existence of complex macromolecular structures, etc).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264454     DOI: 10.1146/annurev.pharmtox.41.1.145

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  224 in total

Review 1.  The many dimensions of cAMP signaling.

Authors:  J H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins.

Authors:  Yuequan Shen; Young-Sam Lee; Sandriyana Soelaiman; Pamela Bergson; Dan Lu; Alice Chen; Kathy Beckingham; Zenon Grabarek; Milan Mrksich; Wei-Jen Tang
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

Review 3.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.

Authors:  Ko-Woon Lee; Jang-Hee Hong; In Young Choi; Yongzhe Che; Ja-Kyeong Lee; Sung-Don Yang; Chang-Woo Song; Ho Sung Kang; Jae-Heun Lee; Jai Sung Noh; Hee-Sup Shin; Pyung-Lim Han
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 5.  The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology.

Authors:  Rennolds S Ostrom; Paul A Insel
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

Review 6.  Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps.

Authors:  Rennolds S Ostrom; Amy S Bogard; Robert Gros; Ross D Feldman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-20       Impact factor: 3.000

Review 7.  Networking with AKAPs: context-dependent regulation of anchored enzymes.

Authors:  Emily J Welch; Brian W Jones; John D Scott
Journal:  Mol Interv       Date:  2010-04

8.  Equilibrium between adenylyl cyclase and phosphodiesterase patterns adrenergic agonist dose-dependent spatiotemporal cAMP/protein kinase A activities in cardiomyocytes.

Authors:  Vania De Arcangelis; Shubai Liu; Dawen Zhang; Dagoberto Soto; Yang K Xiang
Journal:  Mol Pharmacol       Date:  2010-06-07       Impact factor: 4.436

9.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

Review 10.  G-protein signaling: back to the future.

Authors:  C R McCudden; M D Hains; R J Kimple; D P Siderovski; F S Willard
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.